作者
Sabine Hombach-Klonisch, Maryam Mehrpour, Shahla Shojaei, Craig Harlos, Marshall Pitz, Ahmed Hamai, Krzysztof Siemianowicz, Wirginia Likus, Emilia Wiechec, Brian D Toyota, Reyhane Hoshyar, Amir Seyfoori, Zahra Sepehri, Sudharsana R Ande, Forough Khadem, Mohsen Akbari, Adrienne M Gorman, Afshin Samali, Thomas Klonisch, Saeid Ghavami
发表日期
2018/4/1
来源
Pharmacology & therapeutics
卷号
184
页码范围
13-41
出版商
Pergamon
简介
Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of brain tumors remains a challenge. This is particularly true for the most frequent and fatal adult brain tumor, glioblastoma (GB). Upon diagnosis, the average survival time of GB patients remains only approximately 15 months. The alkylating drug temozolomide (TMZ) is routinely used in brain tumor patients and induces apoptosis, autophagy and unfolded protein response (UPR). Here, we review these cellular mechanisms and their contributions to TMZ chemoresistance in brain tumors, with a particular emphasis on TMZ chemoresistance in glioma stem cells and GB.
学术搜索中的文章
S Hombach-Klonisch, M Mehrpour, S Shojaei, C Harlos… - Pharmacology & therapeutics, 2018